Lakewood-amedex Biotherapeutics Inc. reported shareholder vote results
SEC 8-KRead source ↗
Lakewood-amedex Biotherapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds6 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 323% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Lakewood-amedex Biotherapeutics Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 211% and a beta of -0.2 against the S&P 500.
- Short interest rising. Shares sold short rose 70% in a month to 7.4% of tradable shares.
Latest results
- Earnings per share
- -$2.75 against an average estimate of -$0.65: missed by 323.1%
Price chart
- 1 day-5.0%
- 1 week-32.1%
- 1 month-79.6%
Loading chart…
Third-party market data · may be delayed
At a glance
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Shareholder vote
- Announcement
Lakewood-amedex Biotherapeutics Inc. made a public disclosure
SEC 8-KRead source ↗
No model value for Lakewood-amedex Biotherapeutics Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Lakewood-amedex Biotherapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lakewood-amedex Biotherapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.57 | −444% | — | — |
| Next | −$1.17 | +75% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +81.3% on 90 days ago. In the last 30 days, 0 analysts raised Lakewood-amedex Biotherapeutics Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.52 | −$1.32 |
| 60 days ago | −$4.96 | −$1.32 |
| 30 days ago | −$4.96 | −$1.32 |
| 7 days ago | −$4.96 | −$1.32 |
| Now | −$4.57 | −$1.17 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.65 | −$2.75 | −323.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 7.4% of tradable shares
- Days to cover
- 0.04 at average volume
- Short interest, 1 month
- +70% to October 15, 2026
- Held by institutions
- 6% of shares
- Held by insiders
- 39.5% of shares
- Employees
- 5 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −85.9%
- vs 200-day average
- —
- Volatility (1 year)
- 211%
- Beta vs S&P 500
- -0.20
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $306,539
- Institutions reporting
- 6
- Positions opened / closed
- 6 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Marex Group Ltd | $151,244 | 48K | 49.3% | — |
| HRT Financial LP | $140,000 | 45K | 45.7% | — |
| UBS Group AG | $12,868 | 4K | 4.2% | — |
| Tower Research Capital LLC (TRC) | $1,959 | 1K | 0.6% | — |
| Osaic Holdings, Inc. | $433 | 0K | 0.1% | — |
| Blue Trust, Inc. | $35 | 0K | 0.0% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lakewood-amedex Biotherapeutics Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- 8-K Current report
- S-1 REGISTRATION STATEMENT
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- S-1 REGISTRATION STATEMENT
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Lakewood-amedex Biotherapeutics Inc. in brief
- What does Lakewood-amedex Biotherapeutics Inc. do?
- Lakewood-amedex Biotherapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Lakewood-amedex Biotherapeutics Inc.'s stock ticker?
- Lakewood-amedex Biotherapeutics Inc. trades under the ticker LABT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Lakewood-amedex Biotherapeutics Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Marex Group Ltd, HRT Financial LP and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Lakewood-amedex Biotherapeutics Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.